Guillain-Barré Syndrome and Menactra Meningococcal Vaccine FAQs

Meningococcal conjugate vaccine (MenACWY-D; Menactra) was approved by the Food and Drug Administration in 2005 and became available for public use. Shortly after, case reports of Guillain-Barré after Menactra vaccination were reported to the Vaccine Adverse Event Reporting System (VAERS). In studies evaluating the possible relationship between Menactra and GBS, the risk of GBS after Menactra, if any, was small.

Does Menactra Meningococcal Conjugate Vaccine cause Guillain-Barré Syndrome (GBS)?

No. Two large studies were conducted to investigate whether GBS was caused by the vaccine or was coincidental with vaccination. These studies included a combined total of over 2 million vaccinated adolescents.  The results of these studies showed that there was no link between Menactra and GBS.

  • A 2012 study used health records of over 9.6 million preteens and teens to evaluate a possible link between Menactra and GBS. The study found that youth who received Menactra were not at increased risk of developing GBS.
  • Another large 2012 study combined the above study with data from the Vaccine Safety Datalink to search for diagnoses of GBS in 11.2 million preteens and teens who received Menactra. This study also found no link between GBS and Menactra and observed 0 confirmed GBS cases.

What is GBS?

GBS is a rare disorder in which a person’s own immune system damages their nerve cells, causing muscle weakness and sometimes paralysis. It often follows infection with a virus or bacteria. Most people recover fully from GBS, but some people have permanent nerve damage. In the United States, an estimated 3,000 to 6,000 people develop GBS each year, whether or not they received a vaccination.

What causes GBS?

Many things can cause GBS, including common infections such as sore throats and other infections that occur in the community.

Have other vaccines ever been suspected of causing GBS?

In 1976, flu vaccine was associated with a rare risk of GBS. The Institute of Medicine (IOM) conducted a thorough scientific review of this issue in 2003 and concluded that people who received the 1976 swine influenza vaccine had an increased risk for developing GBS. Scientists have multiple theories on why this increased risk may have occurred, but the exact reason for this association remains unknown.

Where can I get more information about meningococcal vaccine?

More information is available on CDC’s Meningococcal Vaccination webpage.

How can I report a case of GBS after Menactra or any vaccine?

Any possible vaccine side effect can be reported to the Vaccine Adverse Event Reporting System (VAERS) to help CDC and the Food and Drug Administration better understand vaccine safety. Anyone can report to VAERS online at or by phone at 1-800-822-7967.